Shenghui Feng

Dr. Shenghui Feng


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
WZWengen Zhu
Wengen Zhu
YZYue Zhou
Yue Zhou
LGLinjuan Guo
Linjuan Guo
SFShenghui Feng
Shenghui Feng
Sialic acids are predominantly found at the terminal ends of glycoproteins and glycolipids and play key roles in cellular communication and function. The process of sialylation, a form of post-translational modification, involves the covalent attachment of sialic acid to the terminal residues of oligosaccharides and glycoproteins. This modification not only provides a layer of electrostatic repulsion to cells but also serves as a receptor for various biological signaling pathways. Sialylation is involved in several pathophysiological processes. Given its multifaceted involvement in cellular functions, sialylation presents a promising avenue for therapeutic intervention. Current studies are exploring agents that target sialic acid residues on sialoglycans or the sialylation process. These efforts are particularly focused on the fields of cancer therapy, stroke treatment, antiviral strategies, and therapies for central nervous system disorders. In this review, we aimed to summarize the biological functions of sialic acid and the process of sialylation, explore their roles in various pathophysiological contexts, and discuss their potential applications in the development of novel therapeutics.

25 July 2023 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
JSJunyi Sun
Junyi Sun
ZXZengshuo Xie
Zengshuo Xie
YWYuzhong Wu
Yuzhong Wu
XLXiao Liu
Xiao Liu
JMJianyong Ma
Jianyong Ma
SFShenghui Feng
Shenghui Feng

12 July 2024 in ESC Heart Failure
Verified
Journal Article
Open access
SXShuo Xu
Shuo Xu
ZGZhenbang Gu
Zhenbang Gu
WZWengen Zhu
Wengen Zhu
SFShenghui Feng
Shenghui Feng
We performed a systematic review and meta-analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023. Two researchers participated in data collection independently. Risk ratios (RRs) from included studies with 95% confidence intervals (CIs) were pooled in the Review Manager version 5.40 software using a random-effects model for analysis. A total of 11 studies (3 post hoc analyses of RCTs and 8 observational studies) with 18 602 participants were included in this meta-analysis. After pooling all the data from eligible studies, our results indicated that COPD was associated with an increased risk of hospitalization (RR = 1.66, 95% CI, 1.47–1.87, P < 0.00001), mortality (RR = 1.62, 95% CI, 1.34–1.95, P < 0.00001), and the composition of hospitalization or mortality (RR = 1.84, 95% CI, 1.35–2.51, P < 0.001) in patients with HFpEF. In a subgroup analysis, the risks of cardiovascular-related mortality (RR = 1.59, 95% CI, 1.30–1.93, P < 0.00001) and post-discharge mortality risk (RR = 2.57, 1.34–4.93, P < 0.01) were increased in HFpEF patients comorbid with COPD, and these associations were also detected in HF-caused hospitalization (RR = 1.64, 95% CI, 1.44–1.87, P < 0.00001). Evidence from existing studies supported that COPD was an independent prognostic risk factor for patients with HFpEF. Developing rapid clinical diagnostic indicators and early use of novel drugs such as SGLT-2 and ARNI may improve the prognosis of this population, deserving further study.

4 December 2025 in Metabolism
Verified
Journal Article
Closed access
MYMin Ye
Min Ye
SFShenghui Feng
Shenghui Feng
ZXZixuan Xu
Zixuan Xu
WHWenfeng He
Wenfeng He
CLChen Liu
Chen Liu
WZWengen Zhu
Wengen Zhu

19 August 2025 in Pharmacological Research
Verified
Journal Article
Open access
SFShenghui Feng
Shenghui Feng
YZYue Zhou
Yue Zhou
LGLinjuan Guo
Linjuan Guo
YLYan Liang
Yan Liang
WZWengen Zhu
Wengen Zhu
Cardiometabolic diseases (CMDs), encompassing both cardiovascular diseases and metabolic syndromes, are among the leading causes of global morbidity and mortality. Protein S-palmitoylation, a reversible lipid-based post-translational modification, has emerged as a crucial regulator of cellular function and homeostasis. Palmitoylation is catalysed by palmitoyl transferases (PATs), also known as ZDHHC (zinc finger Asp-His-His-Cys) proteins, while a series of deacylases mediate the process of depalmitoylation. By modulating protein hydrophobicity, stability, subcellular localization, enzymatic activity, and membrane trafficking, palmitoylation exerts profound effects on cellular function. Physiologically, maintaining normal palmitoylation-depalmitoylation cycle are crucial in regulating the activity and membrane localization of ion channels involved in cardiomyocyte electrophysiology, modulating endothelial metabolism, cell-cell interactions, and repair following vascular injury, as well as influencing insulin signalling in cardiomyocyte metabolism. In the aspect of pathogenesis, palmitoylation influences the development of CMDs such as coronary artery disease (CAD), heart failure (HF), hypertension, type 2 diabetes (T2D), diabetic cardiomyopathy (DbCM), obesity, and non-alcoholic fatty liver disease (NAFLD). Dysregulation of the palmitoylation-depalmitoylation cycle contributes to these pathological processes, exacerbating disease progression. This review systematically explores the biological functions of palmitoylation in cardiometabolic physiology and diseases, discussing potential therapeutic targets within the palmitoylation pathway. By maintaining normal palmitoylation-depalmitoylation cycle and preventing its dysregulation, novel strategies for the prevention and treatment of CMDs may be developed.